Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk: The Debate Is over

Allan D. Sniderman; Ann Marie Navar; George Thanassoulis

doi:10.1001/jamacardio.2021.5080

Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk: The Debate Is over

Allan D. Sniderman, Ann Marie Navar, George Thanassoulis

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Journal	JAMA Cardiology
DOIs	https://doi.org/10.1001/jamacardio.2021.5080
State	Accepted/In press - 2021
Externally published	Yes

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1001/jamacardio.2021.5080

Cite this

@article{b26f3ce37ee041d9ab3bb38654b757bc,

title = "Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk: The Debate Is over",

author = "Sniderman, {Allan D.} and Navar, {Ann Marie} and George Thanassoulis",

note = "Funding Information: has participated in advisory boards/speaker bureau for Amgen, Regeneron/Sanofi, HLS Therapeutics, Ionis, Servier, and Novartis and has received grant funding from Servier and Ionis. Dr Navar has received funding for research to her institution from Bristol Myers Squibb, Esperion, Amgen, and Janssen and honoraria and consulting fees from Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Bayer, CSL, Esperion, Janssen, Lilly, Sanofi, Regeneron, Novo Nordisk, Novartis, The Medicines Company, New Amsterdam, Cerner, 89bio, ZiZi, and Pfizer. No other disclosures were reported.",

year = "2021",

doi = "10.1001/jamacardio.2021.5080",

language = "English (US)",

journal = "JAMA Cardiology",

issn = "2380-6583",

publisher = "American Medical Association",

}

TY - JOUR

T1 - Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk

T2 - The Debate Is over

AU - Sniderman, Allan D.

AU - Navar, Ann Marie

AU - Thanassoulis, George

N1 - Funding Information: has participated in advisory boards/speaker bureau for Amgen, Regeneron/Sanofi, HLS Therapeutics, Ionis, Servier, and Novartis and has received grant funding from Servier and Ionis. Dr Navar has received funding for research to her institution from Bristol Myers Squibb, Esperion, Amgen, and Janssen and honoraria and consulting fees from Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Bayer, CSL, Esperion, Janssen, Lilly, Sanofi, Regeneron, Novo Nordisk, Novartis, The Medicines Company, New Amsterdam, Cerner, 89bio, ZiZi, and Pfizer. No other disclosures were reported.

PY - 2021

Y1 - 2021

UR - http://www.scopus.com/inward/record.url?scp=85119278822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85119278822&partnerID=8YFLogxK

U2 - 10.1001/jamacardio.2021.5080

DO - 10.1001/jamacardio.2021.5080

M3 - Comment/debate

C2 - 34773457

AN - SCOPUS:85119278822

SN - 2380-6583

JO - JAMA Cardiology

JF - JAMA Cardiology

ER -

Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk: The Debate Is over

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this